10-Q: SCWorx Reports Widened Losses, Going Concern Doubts

SCWorx Corp. reported a significantly increased net loss for Q3 2025, raising substantial doubt about its ability to continue as a going concern, alongside a Nasdaq minimum bid price deficiency.

Summary

• SCWorx Corp. reported a net loss of $1,312,539 for the three months ended September 30, 2025, a significant increase from $424,963 for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $3,694,927, compared to $940,935 for the nine months ended September 30, 2024.
• Revenue decreased to $705,799 for the three months ended September 30, 2025, from $759,724 in the prior year, primarily due to contract expirations and non-renewals.
• Nine-month revenue also declined to $2,108,730 in 2025 from $2,313,850 in 2024.
• The company's accumulated deficit reached $34,670,993 as of September 30, 2025.
• Management has concluded that conditions exist that raise substantial doubt about the company's ability to continue as a going concern.
• SCWorx received a Nasdaq notification for not meeting the $1 minimum bid price requirement and has been granted an extension until April 6, 2026, to regain compliance.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to design deficiencies and lack of segregation of duties.
• Cash and cash equivalents increased to $684,295 as of September 30, 2025, from $106,654 at December 31, 2024, largely due to financing activities.
• The company issued a significant number of common shares for legal settlements, convertible loan conversions, and warrant exercises, leading to substantial share dilution.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to a significantly widened net loss, declining revenue, explicit 'going concern' warning, ineffective disclosure controls, and the Nasdaq minimum bid price deficiency. While cash increased from financing, this is offset by the substantial dilution and the underlying operational challenges.

Positives

• Cash balance increased significantly to $684,295 as of September 30, 2025, from $106,654 at December 31, 2024.
• Total current assets increased to $1,333,316 as of September 30, 2025, from $503,378 at December 31, 2024.
• Total current liabilities decreased to $1,176,306 as of September 30, 2025, from $1,836,549 at December 31, 2024.
• Gross profit for the three months ended September 30, 2025, improved to $251,927 compared to $132,576 in the same period of 2024.
• Operating expenses decreased by $135,290 for the three months and $131,049 for the nine months ended September 30, 2025, primarily due to reduced legal and professional fees.
• Nasdaq granted a 180-day extension until April 6, 2026, to regain compliance with the minimum bid price rule.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly widened to $3,694,927 from $940,935 in the prior year.
• Revenue decreased by $205,120 (8.9%) for the nine months ended September 30, 2025, primarily due to contract expirations and non-renewals.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and expected continued cash outflows.
• Disclosure controls and procedures were concluded to be ineffective as of September 30, 2025, due to design deficiencies and lack of segregation of duties.
• Interest expense and amortization of debt discounts increased significantly, contributing to the higher net loss.
• The company faces a Nasdaq minimum bid price deficiency, with potential delisting if compliance is not regained by April 6, 2026.
• Significant share dilution occurred due to the issuance of common stock for legal settlements, convertible loan conversions, and warrant exercises.
• Common stock equivalents outstanding (58,054,640) exceed the total number of authorized shares (45,000,000), although some are restricted.

Risks

• Inability to reverse the recent decline in revenue and resume growing revenue.
• Failure to resolve various litigation proceedings on favorable terms or at all.
• Inability to obtain additional financing in sufficient amounts or on acceptable terms to fund the business plan.
• Dependence on third-party subcontractors to perform some contract work.
• Adverse impact of new or changed laws, regulations, or industry standards.
• Challenges in adopting and mastering new technologies and adjusting fixed costs to evolving industry and customer demands.
• Impact of changes in general market, economic, and political conditions.
• Substantial doubt about the company's ability to continue as a going concern within one year.
• Potential delisting from Nasdaq due to failure to maintain a minimum bid price of $1 per share.
• Ineffectiveness of disclosure controls and procedures due to design deficiencies and lack of segregation of duties.

Future Outlook

Management expects operating losses to continue for the foreseeable future and will need to generate significant increases in product revenues to achieve profitability. Operating expenses are anticipated to remain relatively flat during the remainder of 2025, with the exception of marketing and advertising. If Nasdaq minimum bid price compliance is not regained within the extended 180-day period, the company plans to implement a reverse stock split.

Management Comments

• "We expect operating expenses to remain relatively flat during the rest of 2025 with the exception of marketing and advertising."
• "Management has concluded that on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025 conditions exist that raise substantial doubt about our ability to continue as a going concern since we may not have sufficient capital resources from operations and existing financing arrangements to meet our operating expenses and working capital requirements."

Industry Context

SCWorx operates in the healthcare information technology sector, providing data content and services for healthcare providers. The industry is characterized by a continuous need for data normalization, interoperability, and big data analytics to improve healthcare processes and information flow. While the demand for such solutions is generally strong, SCWorx's declining revenue and significant losses suggest challenges in market penetration, competitive positioning, or customer retention within this dynamic environment. The company's focus on direct sales and strategic partnerships is a common industry approach, but its recent performance indicates a struggle to convert these efforts into sustainable revenue growth.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The company settled the CorProminence d/b/a Core IR AAA Arbitration case, which awarded Core IR $461,856. A judgment of approximately $502,000 (including interest) was obtained. The company agreed to issue Core IR shares of its common stock with a value of $502,000 in full satisfaction of the judgment. Shares were issued in tranches on July 18, 2024 (159,776 shares), March 14, 2025 (191,250 shares), May 1, 2025 (230,000 shares), and May 21, 2025 (180,000 shares).

Related Party Transactions

• As of September 30, 2025, the company had a payable of $149,838 due to an officer for contract work performed prior to becoming an officer.
• A shareholder advance of $67,622 from the company's former CEO and shareholder was fully repaid as of September 30, 2025.
• Advances from the company's CFO totaling $128,479 for short-term capital requirements between January 18, 2024, and July 11, 2024, were fully repaid as of December 31, 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution from ongoing issuance of shares for debt conversion and warrant exercises. The Nasdaq minimum bid price deficiency and 'going concern' warning pose substantial risks to investment value and liquidity. The stock is at risk of delisting.
• **Creditors:** The company has pledged all assets as collateral for senior secured convertible notes, indicating a higher risk profile for unsecured creditors. The 'going concern' doubt raises concerns about the company's ability to meet future obligations.
• **Employees:** Increased salaries and wages suggest some investment in human capital, but the overall financial instability and 'going concern' warning could create job insecurity.
• **Customers:** Declining revenue due to contract expirations and non-renewals suggests potential dissatisfaction or competitive pressures, which could impact future service reliability or innovation.
• **Management:** Responsible for addressing the 'going concern' issues, regaining Nasdaq compliance, and rectifying ineffective disclosure controls, indicating significant operational and strategic challenges ahead.

Next Steps

• Regain compliance with Nasdaq's $1 minimum bid price requirement by April 6, 2026, potentially through a reverse stock split.
• Generate significant increases in product revenues to achieve profitability and address the going concern issue.
• Address deficiencies in the design of internal controls and lack of segregation of duties to improve disclosure controls and procedures.
• Monitor common stock trading price to ensure Nasdaq compliance.

Key Dates

Recommendation

The filing presents a highly concerning financial picture for SCWorx. The significant widening of net losses, coupled with declining revenue, indicates a deteriorating operational performance. The explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag for investors, suggesting a high risk of insolvency or significant restructuring. The Nasdaq minimum bid price deficiency, with the potential need for a reverse stock split, further highlights the company's precarious market position and could lead to delisting. The ineffectiveness of disclosure controls points to fundamental governance and operational weaknesses. While the company has raised capital through convertible notes and warrant exercises, this has led to substantial share dilution, which is detrimental to existing shareholders. The overall financial health and outlook are extremely poor, warranting a strong sell recommendation.

Keywords

Healthcare IT, Data Normalization, Interoperability, Big Data Analytics, SaaS, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Decline, Going Concern, Nasdaq Delisting, Share Dilution, Convertible Debt, Warrants, Internal Controls